CHARACTERISTICS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IN RSUP DR. M. DJAMIL PADANG

Muslimah Utami Raihani; Mefri Yanni; Ennesta Asri

Authors

Muslimah Utami Raihani Universitas Andalas
Mefri Yanni Universitas Andalas
Ennesta Asri Universitas Andalas

Keywords:

Patient characteristics, Pulmonary arterial hypertension

Abstract

Background: Pulmonary arterial hypertension (PAH) requires a series of physical and supporting examinations to reach diagnosis, recognizing basic characteristics, cardiac structure, and hemodynamic is expected to speed up diagnosis and prevent delays in therapy. Methods: This study is a descriptive observational study with retrospective approach conducted in 45 patients with high probability of PAH through echocardiographic examination. Results: Most people with PAH are women (73.3%) aged 55-64 years (22.2%). The most common chief complaint was shortness of breath (66.7%) with WHO-FC II (47.6%). A total of 68.9% of PAH patients had congenital heart disease. On ECG, most patients did not experience arrythmia (71.7%), with 22.2% patients had right atrial enlargement, 48.9% patients had right axis deviation, 39.2% patients had right ventricular hypertrophy, and 44.4 % experienced right bundle branch block. Chest radiography found cardiomegaly in 64.4% patients. Echocardiographic examination found 45.2% right atrial dilatation and 45.2% right ventricular dilatation, with mean MPAP 52.2±39.4 mmHg, and mean SPAP 79.3±27.6 mmHg. The most frequently used type of therapy was PDE-5 inhibitor (59.5%). Conclusion: Patients enrolled were mostly adult women who had shortness of breath and a history of congenital heart disease. Sinus rhythm was common, but right heart enlargement and RBBB were still found in ECG. Cardiomegaly is also commonly found in PAH patients, and there is an increased mean of MPAP and SPAP on echocardiographic examination. The most commonly used therapy is PDE-5 inhibitor

Downloads

Download data is not yet available.

References

Vonk Noordegraaf A, Groeneveldt JA, Bogaard HJ. Pulmonary hypertension. Eur Respir Rev. 2016;25(139):4–11.

Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):1–12.

Chang W, Weng S, Hsu C, Shih J, Wang J, Wu C. Prognostic factors in patients with pulmonary hypertension — a nationwide cohort study. Am Hear Assoc. 2016;1–11.

Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 SUPPL.):34–9.

Frost AE, Badesch DB, Barst RJ, Benza RL, Gregory Elliott C, Farber HW, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: How REVEAL differs from historic and non-US contemporary registries. Chest. 2011;139(1):128–37.

Ronald J. Oudiz. Death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188(3):267–9.

Dinarti LK, Anggrahini DW, Lilyasari O, Siswanto BB, Hartopo AB. Pulmonary arterial hypertension in Indonesia: Current status and local application of international guidelines. Glob Heart. 2021;16(1):1–11.

Hoeper MM, Gibbs JSR. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev. 2014;23(134):450–7.

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67–119.

Maron BA, Galiè N. Pulmonary Arterial Hypertension Diagnosis, Treatment, and Clinical Management in the Contemporary Era HHS Public Access. JAMA Cardiol. 2016;1(9):1056–65.

Morrell NW. Pulmonary hypertension due to BMPR2 mutation: A new paradigm for tissue remodeling? Proc Am Thorac Soc. 2006;3(8):680–6.

Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci. 2011;120(9):357–75.

McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: Epidemiology and registries. J Am Coll Cardiol. 2013;62(25 SUPPL.).

Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD, et al. The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: A descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovasc Disord. 2020;20(1):1–11.

Duffels MGJ, Engelfriet PM, Berger RMF, van Loon RLE, Hoendermis E, Vriend JWJ, et al. Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120(2):198–204.

Mercurio V, Peloquin G, Bourji KI, Diab N, Sato T, Enobun B, et al. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ. 2018;8(2).

Trow TK, McArdle JR. Diagnosis of Pulmonary Arterial Hypertension. Clin Chest Med. 2007;28(1):59–73.

Bernardo RJ, Haddad F, Couture EJ, Hansmann G, de Jesus Perez VA, Denault AY, et al. Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. Cardiovasc Diagn Ther. 2020;10(5):1580–603.

Falk E, Fuster V. Pulmonary Hypertension. In: Hurst’s The Heart. 14th ed. New York: McGraw-Hill; 2017. p. 17885–1809.

Allison JD, Macedo FY, Hamzeh IR, Birnbaum Y. Correlation of right atrial enlargement on ECG to right atrial volume by echocardiography in patients with pulmonary hypertension. J Electrocardiol [Internet]. 2017;50(5):555–60. Available from: http://dx.doi.org/10.1016/j.jelectrocard.2017.04.012

Chemla D, Humbert M, Sitbon O, Montani D, Hervé P. Systolic and mean pulmonary artery pressures: Are they interchangeable in patients with pulmonary hypertension? Chest. 2015;147(4):943–50.

Casa LDC, Dolensky JR, Spinner EM, Veledar E, Lerakis S, Yoganathan AP. Impact of pulmonary hypertension on tricuspid valve function. Ann Biomed Eng. 2013;41(4):709–24.

Lilyasari O, Subekti Y, Atika N, Dinarti LK, Putri S, Opitasari C, et al. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. BMC Health Serv Res. 2019;19(1):1–9.